A Study of BBO-8520 Alone and in Combination With Pembrolizumab in People With Lung Cancer

Full Title

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Kathryn Arbour’s office at 646-608-3792.

Protocol

25-367

Phase

Phase I (phase 1)

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Kathryn C. Arbour

Co-Investigators

Piro Lito
Gregory J. Riely

Diseases

Lung Cancer › Lung Cancer, Non-Small Cell

Locations

Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau

ClinicalTrials.gov ID

NCT06343402

ClinicalTrials.gov

Visit ClinicalTrials.gov for full clinical trial description